The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression in Intensive Care Clinic
Launched by GULHANE TRAINING AND RESEARCH HOSPITAL · May 27, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a tool called the renal resistive index (RRI) to see if it can help predict how acute kidney injury (AKI) progresses in patients being treated in intensive care. AKI is a serious condition where the kidneys suddenly start to work poorly, which can lead to complications. The researchers want to find out if measuring the RRI, a non-invasive test that looks at how well blood is flowing to the kidneys, can help doctors decide when patients might need further treatment, like dialysis.
To join the study, participants need to be over 18 years old and have been diagnosed with early stages of AKI within the first day of being admitted to the hospital. They should not have certain conditions, such as severe kidney problems or heart issues. If eligible, participants can expect to undergo the RRI test and be monitored closely during their hospital stay. This research is important because it could lead to better ways to identify and treat patients with AKI, ultimately improving their chances of recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Being over 18 years of age
- • 2. Having KDIGO stage 1 or stage 2 acute kidney injury within the first 24 hours of admission
- Exclusion Criteria:
- • 1. Patients who did not provide a consent form for participation in the study 2. Patients under 18 years of age 3. Pregnant women 4. Patients with postrenal acute kidney injury 5. Patients 24 hours after the diagnosis of acute kidney injury 6. Patients with acute kidney injury in the recovery period 7. Patients who were evaluated as KDIGO ABH stage 3 during hospitalization 8. Patients with a known history of renal artery stenosis 9. Patients with a diagnosis of cardiac arrhythmia 10. Patients with a diagnosis of chronic kidney disease and a glomerular filtration rate below 30 ml/min/1.73m2 11. Patients with intra-abdominal pressure above 20 mmHg 12. Patients with a hospitalization period of less than 24 hours
About Gulhane Training And Research Hospital
Gulhane Training and Research Hospital is a leading healthcare institution dedicated to advancing medical knowledge and patient care through innovative clinical research. Located in Turkey, the hospital serves as a prominent center for training healthcare professionals and conducting rigorous clinical trials across various medical fields. With a commitment to excellence, Gulhane integrates cutting-edge technology and evidence-based practices to enhance therapeutic outcomes and contribute to the global medical community. The hospital's collaborative approach fosters partnerships with academic institutions and industry leaders, ensuring the highest standards of ethical conduct and scientific integrity in all research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Türkiye, Turkey
Ankara, , Turkey
Patients applied
Trial Officials
Gürhan T associate professor doctor
Study Director
Gulhane Education and Research Hospital Ankara Türkiye
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported